SCHEMBL23770770

SCHEMBL23770770

Cc1ccc(F)cc1-c1nc(NSc2cccc(N3CCNCC3)n2)ccc1C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 1/20 0.38
CYP1A2 P05177 3/20 0.37
CYP2C9 P11712 1/20 0.37
ABL1 P00519 1/20 0.35
BPTF Q12830 1/20 0.35
CYP2C19 P33261 1/20 0.35
HTR2C P28335 3/20 0.34
SOS1 Q07889 3/20 0.33
KARS1 Q15046 1/20 0.33
WDR5 P61964 1/20 0.33
CHEK1 O14757 2/20 0.33
HTR3E A5X5Y0 1/20 0.33
HTR3B O95264 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HTR3A P46098 1/20 0.33
HTR3D Q70Z44 1/20 0.33
HTR3C Q8WXA8 1/20 0.33
RAF1 P04049 1/20 0.33
BRAF P15056 1/20 0.33
CDK7 P50613 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23770452 0.91 PDE10A (0.34) ABL1
SCHEMBL23770466 0.90 CYP1A2 (0.37) CYP1A2ABL1CYP2C19SOS1WDR5
SCHEMBL23770663 0.89 CYP1A2 (0.43) ADRB2CYP1A2CYP2C9BPTFCYP2C19
SCHEMBL23770791 0.89 PRKCQ (0.34) HTR2CWDR5
SCHEMBL23770684 0.89 ADRB2 (0.36) ADRB2CYP1A2CYP2C9CYP2C19HTR2C
SCHEMBL23770632 0.88 ADRB2 (0.42) ADRB2CYP1A2CYP2C9BPTFCYP2C19
SCHEMBL23770808 0.88 HTR3E (0.38) CYP1A2ABL1BPTFHTR2CCHEK1
SCHEMBL23770431 0.86 GHSR (0.36) WDR5
SCHEMBL23770453 0.86 CYP1A2 (0.40) ADRB2CYP1A2CYP2C9BPTFCYP2C19
SCHEMBL23770444 0.86 ADRB2 (0.42) ADRB2CYP1A2CYP2C9BPTFCYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3504194-B1 N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE NOVARTIS AG (CH) 2021-08-18 EP disclosed